LIFEARC

Registered charity 1015243 · accounts filings on the Charity Commission register · also known as MEDICAL RESEARCH COUNCIL TECHNOLOGY, MRC COLLABORATIVE CENTRE · also registered in Scotland as SC037861 (OSCR)

SIC Code: 72110 - Research and experimental development on biotechnology1. Performing our own research in order to progress technologies and treatments for the benefit of human health.2. Work with universities, charities, public bodies and industry to accelerate the progression of biomedical discoveries to develop new treatments or therapeutics for the medical profession and public.

Causes: The Advancement Of Health Or Saving Of Lives · website · Get email alerts

Financial health, per its FY2024 accounts

The accounts state that LifeArc reported a significant surplus of £182.6 million from royalties and contract income, resulting in total unrestricted reserves of £1.6 billion. The trustees confirm that the organization has adequate liquid reserves and no material uncertainties regarding its ability to continue as a going concern. Financial sustainability is supported by a diverse investment portfolio and long-term planning to manage time-limited royalty income.

Automated summary of the FY2024 accounts; the evidenced findings below carry the verbatim passages.

What the accounts disclose

Accounts audited by Moore Kingston Smith LLP. Discloses 3 of 6 completeness components.

Leadership, per the charity’s website

• Sam Barrell — Chief Executive Officer (CEO) (source)
• Dr Ian Gilham — Chair of Board of Trustees (source)
• Stéphane Maikovsky — Deputy Chief Executive Officer and Chief Financial Officer (source)
• Jonathan Morgan — Chief Medical Officer (source)
• Adrien Lemoine — Chief Business Officer (source)
• Karen Skinner — Chief Operating Officer (source)
• George Orphanides — Chief Scientific Officer (source)
• Claire Pimm — Chief Communications Officer (source)

Listed on the charity’s own website when we last crawled it; roles may have changed. Pay-band disclosures above are anonymous statutory disclosures and are not attributed to any named individual.

Funders the charity credits

Named as funders/supporters on the charity’s own website (the charity’s claim, distinct from accounts-verified grants).

• Gates Foundation — “Gates Foundation: A $5 million partnership to make monoclonal antibodies more accessible” (source page)
• Muscular Dystrophy UK — “Muscular Dystrophy UK: A £1 million partnership to find new treatments for congenital muscular dystrophy” (source page)
• Great Ormond Street Hospital Charity — “Funding: Partnering with Great Ormond Street Hospital Charity (GOSH Charity) to deliver translational research accelerator grants” (source page)

UK research funding (UKRI Gateway to Research)

• Understanding the essential requirement for HDAC1 and HDAC2 in tissue development and homeostasis: implications for disease and therapy. —
• The role of plasma membrane calcium ATPase 4 (PMCA4) in modulating Plasmodium infection and malaria severity —
• Digital Health: OptiMuscle - Improving health outcomes through the optimization of muscle function —
• Understanding pharmacokinetic - pharmacodynamic determinants of outcome to inform dose optimisation for non-MDR TB re-treatment patients in Vietnam —
• Bilateral BBSRC-SFI: Understanding the impact of divergent Sin3A/HDAC1 complex assemblies in gene regulation —
• Deciphering the function of intrinsically disordered protein regions in a cellular context —
• Novel analgesics based on antagonism of TRPV1-AKAP79 binding —
• CHNUK: Integrated platforms from science to policy in response to antibacterial resistance —
• Understanding the contribution of inositol phosphate signalling to class-1 HDAC complex function —
• Development of sustainable academic-industry partnerships: Untapping breakthrough innovation for the treatment and management of infectious diseases —

Structured financials (annual return, FY ending 31/12/2025)

Reported reserves equal ~187.9 months of spending — in the top quarter for charities its size (median 4.6 months; benchmarks).

Per its annual return, largest income source: Charitable activities (87% of income) — components as reported reconcile to the return’s total income; not from the accounts narrative.

Per its annual return, cost of raising funds: 3.4% of total income — below the median for charities its size (3.8%) (benchmarks).

Trustees · trustee networks

• Daniel Morgan
• David Zahn
• Dr Ian David Gilham
• Dr Samantha Marney
• Dr Sameer Mistry
• Dr Teresa Cooper
• Ian James Nicholson
• Joanne Patra Pisani · trustee of 2 other charities
• PANKAJ DAVE
• Paul Nioi
• Stephane Maikovsky
• Susan Jean Wallcraft

Trustee list from the Charity Commission register (current, not historical).

Operates in: Scotland · Throughout England And Wales

Income and spending

Common questions

Known funders

Grants to this charity found in funders’ own accounts filings.

Funders of similar charities

Funders whose accounts show grants to charities similar to this one (and no recorded grant to this charity) — a starting list for fundraisers.

Charities like this

Semantically similar by activities and financial character, from our analysed corpus. Compare with UK BIOBANK LIMITED.

• UK BIOBANK LIMITED income £68.9m
• ASSOCIATION OF MEDICAL RESEARCH CHARITIES income £1.3m
• EARLHAM INSTITUTE income £14.1m
• LIVERPOOL LIFE SCIENCE ACCELERATOR LIMITED income £1.1m
• THE LORNA AND YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION income £508k
• THE COMPANY OF BIOLOGISTS income £8.4m

Side by side with its peers

Each row is that charity’s latest analysed filing; every value is quote-backed on its own page.